Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Peru struggles to contain hepatitis B outbreak:

This article was originally published in Clinica

Executive Summary

There has been a significant fall in the number of cases of hepatitis B reported so far this year in Peru, compared with the same period in 2001, but the health ministry remains on major alert. At the end of July 2002, the Peruvian health ministry's general office of epidemiology (OGE) reported 628 suspected cases, of which 356 had been confirmed, compared with 757 over the same period in 2001. The regions deemed at highest risk are Amazonas, Loreto, San Martin, Pasco, Ucayali, Cusco, Madre de Dios and Apurimac. The government has warned of the difficulty in diagnosing the disease and has launched a public awareness campaign and vaccination programme to help tackle the problem.

You may also be interested in...

Sandoz Denosumab Biosimilar Progressing Faster Than Anticipated

Sandoz announced more than a year ago that its GP2411 biosimilar denosumab candidate had entered the clinic. Management provided an update on its progress at the recent Virtual Meet Novartis Management Investor Event.

Dr Reddy's Adds To OTC Portfolio With Glenmark Deal

Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.

Sandoz Launches US Awareness Campaign

Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts